For US Healthcare Professionals

For US HCPs

Order now
GSK Meningitis Vaccines logo
Order now
    Order now

    Recommendations for meningococcal vaccination in healthy adolescents and teens using the GSK portfolio.1-5

    Not actual patients.
    Vaccination may not protect all recipients.

    You can help protect your patients using GSK's meningococcal vaccines.1-3

    Infographic showing vaccine recommendations by age group

    AAP recommends4:

    • MenACWY: Routine administration of MenACWY vaccines like MENVEO
    • MenB: Using shared clinical decision-making (SCDM)* for MenB vaccines like BEXSERO
    • MenABCWY: Using a MenABCWY vaccine like PENMENVY as an alternative to separate administration of MenACWY and MenB vaccines

     

    The CDC also has meningococcal vaccine recommendations.

     

    *Unlike routine, catch-up, and risk-based recommendations, shared clinical decision-making vaccinations are individualized and guided by discussions between the healthcare provider and the patient or parents/guardian.5,6

     

    FDA-approved prescribing information:

    • The FDA-approved Prescribing Information for PENMENVY states a 2-dose schedule2
    • The FDA-approved Prescribing Information for MENVEO and BEXSERO does not include clinical data on concomitant administration of MENVEO and BEXSERO at the same visit1,3
    • The FDA-approved Prescribing Information for BEXSERO states doses should be administered according to a 2- or 3-dose schedule. The choice of dosing schedule may depend on the risk of exposure and the individual's susceptibility to meningococcal serogroup B disease3

     

    States, municipalities, or systems also may have applicable recommendations. Please consult those for more information.

     

    PENMENVY was studied in MenACWY conjugate vaccine-experienced individuals who previously received either MENVEO or Menactra.2,† CDC states MenACWY vaccines are interchangeable; the same vaccine product is recommended, but not required, for all doses.7

     

    AAP and CDC state that BEXSERO and another manufacturer’s MenB vaccines are not interchangeable4,7; administer BEXSERO for subsequent MenB doses after PENMENVY where MenACWY is not indicated.8

    †Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) is a registered trademark of Sanofi Pasteur Inc., its affiliates and subsidiaries.

     

    AAP=American Academy of Pediatrics; CDC=Centers for Disease Control and Prevention; FDA=Food and Drug Administration; MenABCWY=meningococcal serogroups A, B, C, W, Y; MenACWY=meningococcal serogroups A, C, W, Y; MenB=meningococcal serogroup B.

    Risks icon

    Help your patients understand the potential benefits and risks of the vaccines that help protect against meningococcal disease.1-3

    Five teens smiling

    AAP vaccine recommendations

    MenACWY vaccination4

    • For healthy teens, AAP recommends vaccination of all adolescents at 11 to 12 years of age with a booster dose at 16 years of age

     

    MenB and MenABCWY vaccination4

    • Use a shared clinical decision-making process to review the potential benefits and risks of MenB vaccination for individual adolescents or young adults (preferred age 16-18 years) who are not at increased risk of disease
    • To help protect against MenB, administer 2 doses, 6 months apart. If Dose 2 is administered earlier than 6 months, administer a third dose at least 4 months after Dose 2
    • To optimize rapid protection against MenB (eg, for students starting college in less than 6 months), a 3-dose series (0, 1-2, 6 months) may be administered
    • To help protect against MenB and MenACWY using 1 vaccine, MenABCWY vaccine may be administered when a teen would otherwise get MenACWY and MenB vaccines at the same visit
    Five teens eating and playing image

    Streamline MenB vaccination

    Implement either BEXSERO or PENMENVY at the 16-year-old visit and finish the MenB series with BEXSERO 6 months later.4,5

     

    • The FDA-approved Prescribing Information for PENMENVY states a 2-dose schedule2
    • The FDA-approved Prescribing Information for BEXSERO states doses should be administered according to a 2- or 3-dose schedule. The choice of dosing schedule may depend on the risk of exposure and the individual's susceptibility to meningococcal serogroup B disease.3
    LEARN ABOUT PENMENVY
    LEARN ABOUT BEXSERO
    Risks icon

    According to AAP and CDC, MenB-containing vaccines from different manufacturers are not interchangeable.4,7

    GSK Meningococcal Vaccines Portfolio icon

    According to guidance from AAP and CDC, combination vaccines like PENMENVY are generally preferred over separate injections of the equivalent component vaccines.8,9

    PENMENVY webinar icon

    PENMENVY webinar

    Register to learn more about PENMENVY and meningococcal vaccination recommendations.

    REGISTER

    Indications and Important Safety Information for PENMENVY, BEXSERO, and MENVEO

    Indications for PENMENVY, BEXSERO, and MENVEO

    Important Safety Information for PENMENVY, BEXSERO, and MENVEO

    Indications for PENMENVY, BEXSERO, and MENVEO

    See full Indications and Important Safety Information below.

     

    PENMENVY is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

    BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

    MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

    Important Safety Information for PENMENVY, BEXSERO, and MENVEO

    • Do not administer PENMENVY to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of PENMENVY, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
    • Do not administer BEXSERO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of BEXSERO or after a previous dose of BEXSERO
    • Do not administer MENVEO to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of MENVEO, to any component of MENVEO, or to any other diphtheria toxoid-containing vaccine
    • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of PENMENVY, BEXSERO, or MENVEO
    • For BEXSERO, the tip cap of the prefilled syringe may or may not be made with natural rubber latex. Natural rubber latex may cause allergic reactions. Please check the carton
    • Syncope (fainting) has occurred in association with administration of PENMENVY, BEXSERO, or MENVEO. Ensure procedures are in place to avoid injury from falling associated with syncope
    • PENMENVY, BEXSERO, or MENVEO may not protect all vaccine recipients, and PENMENVY or BEXSERO may not protect against all meningococcal serogroup B strains
    • Immunocompromised persons and some individuals receiving immunosuppressant therapy may have reduced immune responses to PENMENVY, BEXSERO, or MENVEO
    • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENMENVY, BEXSERO, or MENVEO
    • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer PENMENVY or MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
    • Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
    • For PENMENVY, the most commonly reported (≥10%) solicited adverse reactions in individuals aged 10 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (92% and 88%), fatigue (51% and 42%), headache (42% and 36%), myalgia (15% and 12%), nausea (15% and 10%), erythema (13% and 12%), and swelling (13% and 12%). The most commonly reported (≥10%) solicited adverse reactions in MenACWY conjugate vaccine-experienced individuals aged 15 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (80% and 74%), headache (41% and 33%), fatigue (40% and 33%), myalgia (15% and 13%), and nausea (15% and 12%)
    • For BEXSERO, the most commonly reported (≥10%) solicited adverse reactions in a Phase 3 clinical trial were pain at the injection site (87%-92%), fatigue (45%-49%), headache (37%-41%), nausea (11%-13%), erythema (10%-15%), myalgia (10%-14%), and swelling (10%-14%)
    • Common solicited adverse reactions with MENVEO among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
    • For MENVEO, in two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation

     

    Prescribing Information for PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine)

     

    Prescribing Information for BEXSERO (Meningococcal Group B Vaccine)

     

    Prescribing Information for MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]

    To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
    1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    References

    1. Prescribing Information for MENVEO.

    2. Prescribing Information for PENMENVY.

    3. Prescribing Information for BEXSERO.

    4. Recommended child and adolescent immunization schedule for ages 18 years or younger. United States 2026. American Academy of Pediatrics. Updated February 5, 2026. Accessed March 3, 2026. https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf

    5. Amin AB, Collins JP, Dong X, et al. Use of the GSK MenACWY-CRM/MenB-4C pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2025. MMWR. 2026;75(1):7-14. doi:10.15585/mmwr.mm7501a2

    6. ACIP shared clinical decision-making recommendations. Centers for Disease Control and Prevention. January 7, 2025. Accessed January 30, 2026. https://www.cdc.gov/acip/vaccine-recommendations/shared-clinical-decision-making.html

    7. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR. 2020;69(RR-9):1-51. doi:10.15585/mmwr.rr6909a1

    8. Meningococcal disease. Meningococcal vaccine recommendations. Centers for Disease Control and Prevention. July 1, 2025. Accessed January 29, 2026. https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html

    9. Combination vaccines. In: Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2024-2027 Report of the Committee on Infectious Diseases (33rd Edition). American Academy of Pediatrics; 2024:65-66. doi:10.1542/9781610027373